Literature DB >> 20972603

Current practices of driving restriction implementation for patients with brain tumors.

Sayana Thomas1, Minesh P Mehta, John S Kuo, H Ian Robins, Deepak Khuntia.   

Abstract

Brain tumors may impair functioning in several neuro-cognitive domains and interfere with sophisticated tasks, such as driving motor vehicles. No formalized national guidelines or recommendations for driving restrictions in patients with brain tumors exist in the US. We created and administered a 24 question survey to 1,157 US medical practitioners, mostly neurosurgeons, radiation oncologists, and medical oncologists, to identify their knowledge of local driving restriction laws and their practice patterns regarding driving restriction instructions to brain tumor patients. Response were collected from 251 (21.7%) and analyzed from 221 (19%) recipients. Seventy-one percent of the respondents indicated they discuss driving recommendations/restrictions with brain tumor patients, with 82% primarily basing this on seizure activity. Approximately 28% of respondents were unsure if they are required by their State's motor vehicle licensing authority to report medically impaired drivers. Respondents felt that longer periods of restriction prior to re-evaluation are warranted in patients with malignant versus benign brain tumors and high versus low grade gliomas. Only 25% of respondents use formal, standardized testing to determine driving eligibility and approximately 31% address driving restrictions in every patient with a brain tumor. This survey highlights the lack of consensus regarding the responsibilities of physicians treating brain tumor patients in designing and enforcing driving restrictions. We propose that a panel of experts generate driving restriction guidelines to be used in conjunction with objective testing of motor and sensory impairment. These would aid practitioners in developing individualized driving restrictions for every brain tumor patient.

Entities:  

Mesh:

Year:  2010        PMID: 20972603     DOI: 10.1007/s11060-010-0439-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  9 in total

Review 1.  The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases.

Authors:  Minesh P Mehta; May N Tsao; Timothy J Whelan; David E Morris; James A Hayman; John C Flickinger; Michael Mills; C Leland Rogers; Luis Souhami
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

2.  Physician reporting of impaired drivers: a new trend in state law?

Authors:  Kristen Snyder; Joseph D Bloom
Journal:  J Am Acad Psychiatry Law       Date:  2004

Review 3.  Helical TomoTherapy in the treatment of central nervous system metastasis.

Authors:  Joseph M Baisden; Stanley H Benedict; Ke Sheng; Paul W Read; James M Larner
Journal:  Neurosurg Focus       Date:  2007-03-15       Impact factor: 4.047

4.  Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

Authors:  Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans
Journal:  Lancet Neurol       Date:  2009-08-07       Impact factor: 44.182

5.  A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone.

Authors:  Eric L Chang; Jeffrey S Wefel; Moshe H Maor; Samuel J Hassenbusch; Anita Mahajan; Frederick F Lang; Shiao Y Woo; Leni A Mathews; Pamela K Allen; Almon S Shiu; Christina A Meyers
Journal:  Neurosurgery       Date:  2007-02       Impact factor: 4.654

Review 6.  Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines.

Authors:  D D Correa; L Maron; H Harder; M Klein; C L Armstrong; P Calabrese; J E C Bromberg; L E Abrey; T T Batchelor; D Schiff
Journal:  Ann Oncol       Date:  2007-02-06       Impact factor: 32.976

Review 7.  Late neurocognitive sequelae in survivors of brain tumours in childhood.

Authors:  Raymond K Mulhern; Thomas E Merchant; Amar Gajjar; Wilburn E Reddick; Larry E Kun
Journal:  Lancet Oncol       Date:  2004-07       Impact factor: 41.316

Review 8.  Neurotoxicity of treatment.

Authors:  Pasquale Calabrese; Uwe Schlegel
Journal:  Recent Results Cancer Res       Date:  2009

9.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors:  Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

  9 in total
  8 in total

1.  To drive or not to drive, that is still the question: current challenges in driving recommendations for patients with brain tumours.

Authors:  Ann Mansur; Alexa Desimone; Sara Vaughan; Tom A Schweizer; Sunit Das
Journal:  J Neurooncol       Date:  2018-01-02       Impact factor: 4.130

2.  Fitness to drive in patients with brain tumours: the influence of mandatory reporting legislation on radiation oncologists in Canada.

Authors:  A V Louie; D P D'Souza; D A Palma; G S Bauman; M Lock; B Fisher; N Patil; G B Rodrigues
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

3.  Multidisciplinary assessment of fitness to drive in brain tumour patients in southwestern Ontario: a grey matter.

Authors:  E Chan; A V Louie; M Hanna; G S Bauman; B J Fisher; D A Palma; G B Rodrigues; A Sathya; D P D'Souza
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

4.  Assessing fitness to drive in brain tumour patients: a grey matter of law, ethics, and medicine.

Authors:  A V Louie; E Chan; M Hanna; G S Bauman; B J Fisher; D A Palma; G B Rodrigues; A Warner; D P D'Souza
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677

5.  The Korean Society for Neuro-Oncology (KSNO) Guideline for Antiepileptic Drug Usage of Brain Tumor: Version 2021.1.

Authors:  Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Jangsup Moon; Min Sung Kim; Young Zoon Kim; Kihwan Hwang; Ji Eun Park; Kyung Hwan Kim; Jin Mo Cho; Wan Soo Yoon; Se Hoon Kim; Young Il Kim; Ho Sung Kim; Yun Sik Dho; Jae Sung Park; Hong In Yoon; Youngbeom Seo; Kyoung Su Sung; Jin Ho Song; Chan Woo Wee; Min Ho Lee; Myung Hoon Han; Je Beom Hong; Jung Ho Im; Se Hoon Lee; Jong Hee Chang; Do Hoon Lim
Journal:  Brain Tumor Res Treat       Date:  2021-04

6.  Driver safety in patients with primary brain tumors.

Authors:  Eduardo Estevis; Kyle R Noll; Mariana E Bradshaw; Jeffrey S Wefel
Journal:  Neurooncol Pract       Date:  2019-04-11

7.  Clinical evaluation of fitness to drive in patients with brain metastases.

Authors:  Cristina Valencia-Sanchez; Vanessa C Gorelkin; Maciej M Mrugala; Akanksha Sharma; Sujay A Vora; Jonathan B Ashman; Thomas B Daniels; Michele Y Halyard; William G Rule; Nan Zhang; Richard J Butterfield; Steven E Schild; Alyx B Porter
Journal:  Neurooncol Pract       Date:  2019-07-03

8.  Driving habits and behaviors of patients with brain tumors: a self-report, cognitive and driving simulation study.

Authors:  Ann Mansur; Megan A Hird; Alexa Desimone; Iryna Pshonyak; Tom A Schweizer; Sunit Das
Journal:  Sci Rep       Date:  2018-03-15       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.